Potent anti-cancer agents
Despite advances in immuno-oncology, many solid tumors remain stubbornly difficult to treat. Aktis is developing a pipeline of multiple precision engineered targeting molecules to deliver the curative power of alpha radiotherapy to a range of cancers including breast, lung, colorectal, bladder, and liver cancers.
282K
new cases of
breast cancer in
US annually
235K
new cases of lung
cancer in US
annually
149K
new cases of
colorectal cancer
in US annually
84K
new cases of
bladder cancer in
US annually
42K
new cases of liver
cancer in US
annually
A pipeline of targeting molecules
Our current proprietary pipeline is comprised of seven programs, including our clinical-stage program targeting Nectin-4. We look forward to sharing more information as the programs advance.
Partner with us
Interested in bringing alpha radiotherapy to the mainstream? Contact us for information about corporate partnership opportunities. Contact Us
